Presenting
Diurnal
Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions.
They are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).
Diurnals expertise and innovative research activities focus on circadian-based endocrinology (mimicking the bodys natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.
Open Orphan
Open Orphan (ORPH) is a rapidly growing niche CRO pharmaceutical services company which is the world leader in testing vaccines and antivirals through the use of human challenge clinical trials. Open Orphan is actively involved in the fight against COVID-19.
